| Polycythemia Vera |
1 |
0.8 |
| White Blood Cell Count |
0 |
0.77 |
| Polycythemia |
0 |
0.53 |
| Thromboembolism |
0 |
0.53 |
| Blood |
0 |
0.44 |
| Thrombosis |
0 |
0.4 |
| Cerebrovascular Accident |
0 |
0.35 |
| Cancer |
0 |
0.25 |
| Neoplasm |
0 |
0.21 |
| Cardiovascular Risk Management |
0 |
0.18 |
| Hematocrit |
0 |
0.17 |
| Clinical Guidelines |
0 |
0.15 |
| Treatment Guidelines |
0 |
0.12 |
| Essential Thrombocytosis |
0 |
0.11 |
| Hypertension |
0 |
0.11 |
| Aspirin |
0 |
0.08 |
| Health Administration |
0 |
0.08 |
| Leukocytosis |
0 |
0.08 |
| Phlebotomy |
0 |
0.08 |
| Acute Leukemia |
0 |
0.07 |
| Congenital Heart Disease |
0 |
0.07 |
| Europe |
0 |
0.06 |
| Heart |
0 |
0.06 |
| Hypoxia |
0 |
0.06 |
| Leukemia |
0 |
0.06 |
| Ethics |
0 |
0.05 |
| Epidemiology |
0 |
0.04 |
| Hemorrhage |
0 |
0.04 |
| Lymphoma |
0 |
0.04 |
| Thrombocytosis |
0 |
0.04 |
| Tobacco Cessation |
0 |
0.04 |
| Tobacco Use |
0 |
0.04 |
| Utah |
0 |
0.04 |
| Electronic Health Record (EHR) |
0 |
0.03 |
| Multiple Myeloma |
0 |
0.03 |
| Patient Safety |
0 |
0.03 |
| Stem Cell Research and Therapy |
0 |
0.03 |
| Adverse Effects |
0 |
0.02 |
| Artificial Intelligence |
0 |
0.02 |
| Cardiovascular disease |
0 |
0.02 |
| Cytokines |
0 |
0.02 |
| Fatigue |
0 |
0.02 |
| Geriatrics |
0 |
0.02 |
| Hemoglobin |
0 |
0.02 |
| Night Sweats |
0 |
0.02 |
| Platelet Count |
0 |
0.02 |
| Primary Care |
0 |
0.02 |
| Prognosis |
0 |
0.02 |
| Pruritus |
0 |
0.02 |
| Quality of Life |
0 |
0.02 |
| Somatic |
0 |
0.02 |
| Splenomegaly |
0 |
0.02 |
| Tolerance |
0 |
0.02 |
| Venous Thromboembolism (VTE) |
0 |
0.02 |